7,097 Shares in AtriCure, Inc. (NASDAQ:ATRC) Purchased by Cowa LLC

Cowa LLC bought a new position in shares of AtriCure, Inc. (NASDAQ:ATRC) during the 4th quarter, HoldingsChannel reports. The institutional investor bought 7,097 shares of the medical device company’s stock, valued at approximately $217,000.

Several other large investors also recently bought and sold shares of the stock. Arcadia Investment Management Corp MI acquired a new stake in AtriCure during the 3rd quarter worth approximately $28,000. Heck Capital Advisors LLC purchased a new position in AtriCure during the fourth quarter worth $60,000. Venturi Wealth Management LLC increased its position in AtriCure by 1,337.6% during the fourth quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company’s stock worth $69,000 after buying an additional 2,100 shares in the last quarter. KBC Group NV increased its position in AtriCure by 65.3% during the fourth quarter. KBC Group NV now owns 2,360 shares of the medical device company’s stock worth $72,000 after buying an additional 932 shares in the last quarter. Finally, R Squared Ltd purchased a new stake in shares of AtriCure in the fourth quarter valued at $89,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on ATRC shares. UBS Group lifted their target price on AtriCure from $35.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. JMP Securities reissued a “market outperform” rating and issued a $60.00 price objective on shares of AtriCure in a report on Monday, February 10th. JPMorgan Chase & Co. boosted their price objective on AtriCure from $40.00 to $51.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Piper Sandler upped their target price on AtriCure from $40.00 to $50.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Finally, Stifel Nicolaus boosted their price objective on AtriCure from $36.00 to $48.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, AtriCure presently has an average rating of “Moderate Buy” and an average target price of $51.56.

AtriCure Stock Performance

ATRC stock opened at $38.39 on Friday. The company has a 50 day moving average price of $36.23 and a 200 day moving average price of $31.85. The stock has a market capitalization of $1.88 billion, a PE ratio of -40.41 and a beta of 1.46. AtriCure, Inc. has a fifty-two week low of $18.94 and a fifty-two week high of $43.11. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.65 and a quick ratio of 2.59.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.